The market swung into a climb late Wednesday, in part after the FOMC meeting minutes showed members believed the rate tightening cycle was nearing its end, signaling a hope that rates have only one direction to go: down. The S&P 500 officially climbed for the first five trading sessions of the new year, a trend that historically signals an 83% likelihood of the market climbing in the year. Since 1950, the ...
OG Kanaka
:
Still a good stock to DCA (dollar cost average) in for the long term. You want quantum exposure for your portfolio you can’t go wrong with stocks like $Alphabet-C (GOOG.US)$ Short term, will see plenty volatility as traders want to make money NOW, not later. Look for short term opportunities as a trader. Long term, just keep buying fractionally. So if you got time on your side, just DCA in general to be on the safer side
JjTern
:
JnJ facing few issues. Starting with what I know in December last year there is the class action lawsuit on their talcum powder product. (mind you this is baby product) And just yesterday they have put a pause on their heart device. Few combination, but don't only look at those big bad news, there are also good signs that is coming out from the company like dividend announcement ahead of time, their internal stock buy back.
$Pfizer (PFE.US)$ The stock is trading above 120 EMA. The trend is likely to be up. Next resistance is 27.56. Once it breaks the resistance, next hit point will be 27.70. The need for new vaccines for H5N1 and rising covid cases in USA are propelling up the stock. Time for Pfizer to shine this year.
2
2
Report
Trade_JM
:
Yes, the time is coming. Very Very soon!
ok
buying time
Once the profit taking is over, the stock will rebound. Covid is here to stay and vaccines will always be needed.
whats happening !
The stock is trading above 120 EMA. The trend is likely to be up. Next resistance is 27.56. Once it breaks the resistance, next hit point will be 27.70. The need for new vaccines for H5N1 and rising covid cases in USA are propelling up the stock. Time for Pfizer to shine this year.
No comment yet